Genetic medicines company Modalis Therapeutics Corporation (Tokyo Stock Exchange: 4883) announced on Monday that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to MDL-101, a novel treatment for congenital muscular dystrophy type 1a (LAMA2-CMD).
This designation applies to serious diseases affecting children under 18, with fewer than 200,000 cases in the US. Should MDL-101 receive marketing approval, Modalis may obtain a Priority Review Voucher (PRV) for expedited FDA review of another product.
LAMA2-CMD is a severe genetic disorder caused by the absence of the LAMA2 protein, which poses challenges for conventional gene therapy development. Modalis' proprietary CRISPR-GNDM technology enables precise modulation of gene expression without DNA breaks. MDL-101 aims to compensate for LAMA2 deficiency by inducing expression of the sister gene, LAMA1, in muscle tissues, potentially providing a one-time, durable treatment.
Modalis is also pursuing an Orphan Drug application for MDL-101, currently under FDA review. The company's mission is to deliver life-changing treatments for rare genetic diseases.
SciTech Development secures second FDA clearance for ST-001 in early-stage cancer trials
ProRx Pharma expands wellness portfolio with launch of four preventative injectables
ResVita Bio's RVB-003 receives US FDA Orphan Drug Designation
Tasman Therapeutics to raise USD175m in Series A funding
Variant's VAR002 receives positive European regulatory feedback
Sanofi's rilzabrutinib receives US orphan drug designation for two rare diseases
Hoth Therapeutics partners with Washington University to advance Alzheimer's disease research
Mabwell's B7-H3-targeting ADC clinical trial application receives Chinese regulatory approval
Amygdala Neurosciences selects ANS-858 as lead clinical candidate for substance use disorder
Quest Diagnostics expands HPV self-collection screening option